Is Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend) Legal? FDA Status and Regulations Explained (2026)

Is Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend) Legal? FDA Status and Regulations Explained (2026)

If you're researching the Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend) legality question, here's the short answer: this specific triple-peptide blend is not FDA-approved for any clinical indication and is classified as research use only. That means a licensed physician cannot legally prescribe it to you, a compounding pharmacy cannot legally prepare it for human use, and buying it online — regardless of what the seller's website says — puts you in a genuine legal grey zone. The longer answer involves understanding how each of the three component peptides sits within the regulatory framework, why the FDA draws the lines it does, and what your actual options are if you're pursuing growth hormone axis optimization through a legitimate clinic.

This article breaks all of that down, component by component and regulation by regulation, so you can make an informed decision rather than guessing.

---

Key Takeaways

• The Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg Blend is not FDA-approved for any human clinical indication and carries a research use only classification as of March 2026.^[1]
• Tesamorelin as a standalone drug (brand name Egrifta SV®) holds FDA approval specifically for HIV-associated lipodystrophy, but this approval does not extend to blended formulations with CJC-1295 or Ipamorelin.^[2]
• CJC-1295 (no DAC) and Ipamorelin individually appeared on the FDA's 503B bulk drug substance "Category 2" list — meaning the FDA has determined they present known safety risks that preclude their use in compounded preparations intended for human use.^[3]
• Vendors selling this blend as "research use only" are not providing a legal loophole — that label does not authorize human use and does not protect buyers from legal or health risk.
• No DEA scheduling currently applies to this blend, but that does not make it legal for human use; it simply means a different regulatory framework (FDA drug approval and compounding law) governs it.
• If you're working with a clinic offering this blend for human administration, that's a significant red flag. Ask hard questions before proceeding.

---

Regulatory Status at a Glance

---

Current FDA Status

The regulatory picture here is more complicated than a simple yes/no — and that complexity is exactly what some clinics and vendors exploit. Let's separate the three components.

Tesamorelin

Tesamorelin (CAS 218949-48-5) is a 44-amino acid synthetic analog of growth hormone-releasing hormone (GHRH). It's the only component of this blend with any FDA approval at all. The FDA approved tesamorelin injection under the brand name Egrifta® in November 2010, and the reformulated version Egrifta SV® received approval in 2019, specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.^[2] That indication is narrow and specific. The approval does not cover general body composition improvement, anti-aging applications, athletic performance, or any indication in non-HIV patients.

Critically, the FDA approval for Egrifta SV® applies to that specific manufactured product — not to tesamorelin as an active pharmaceutical ingredient that any pharmacy can freely compound. When tesamorelin is mixed into a multi-peptide blend, the resulting formulation has no FDA approval whatsoever.

CJC-1295 (No DAC)

CJC-1295 without Drug Affinity Complex (also called Modified GRF 1-29, or Mod GRF 1-29) is a truncated, stabilized GHRH analog. It has no FDA-approved indication for any condition.^[1] The FDA evaluated CJC-1295 as part of its bulk drug substance review process for compounding pharmacies and determined it does not meet the criteria for inclusion on the list of substances that can be compounded for human use. The agency's concern centers on the lack of clinical safety data and the potential for immunogenicity — meaning the body may generate antibodies against synthetic peptide analogs, with unpredictable downstream consequences.^[3]

Ipamorelin

Ipamorelin (CAS 170851-70-4) is a pentapeptide ghrelin mimetic and selective growth hormone secretagogue receptor (GHS-R1a) agonist. Like CJC-1295, it has no FDA-approved human indication and has been evaluated — and excluded — from the FDA's list of bulk drug substances that can be compounded.^[3] The FDA's reasoning for both peptides follows the same logic: insufficient human safety data, no approved drug application, and concerns about immunogenicity risk in compounded injectable preparations.

The Blend as a Whole

A formulation combining all three — tesamorelin, CJC-1295 (no DAC), and ipamorelin at a combined 12mg dose — has no regulatory pathway that makes it legal for human clinical use in the United States as of March 2026. The presence of FDA-approved tesamorelin in the mixture does not "upgrade" the blend's legal status. If anything, combining an approved drug with unapproved components creates additional regulatory complications.

---

Compounding Status

This is where most of the confusion in the peptide therapy space originates. Compounding pharmacies operate under two main regulatory frameworks: Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which covers traditional patient-specific compounding, and Section 503B, which covers outsourcing facilities that can produce larger batches without individual prescriptions.^[4]

Both pathways require that the bulk drug substances used in compounding appear on an FDA-approved list, are components of an FDA-approved drug, or meet specific criteria established by the agency. The FDA has been working through a formal review process to evaluate peptides for inclusion or exclusion from these lists.

CJC-1295 and Ipamorelin: Category 2 Status

The FDA placed both CJC-1295 and Ipamorelin on the Category 2 bulk drug substance list — the list of substances that the FDA has evaluated and determined should not be used in compounded preparations.^[3] Category 2 placement is not a temporary hold or a "pending" status. It reflects an affirmative FDA determination that the substance presents safety concerns or lacks sufficient evidence to support compounding for human use.

The specific concerns the FDA has raised about peptide secretagogues in this category include:

• Immunogenicity risk: Synthetic peptide analogs can trigger antibody formation, potentially causing hypersensitivity reactions or neutralizing the therapeutic effect of endogenous hormones.^[3]
• Lack of adequate clinical data: Neither peptide has completed Phase III clinical trials establishing safety and efficacy in humans at the doses used in compounded preparations.
• Sterility and stability concerns: Injectable compounded peptides carry inherent sterility risks that are amplified when clinical evidence for the formulation is absent.

What This Means for 503A Pharmacies

A 503A compounding pharmacy — the kind that fills individual patient prescriptions — cannot legally compound CJC-1295 (no DAC) or Ipamorelin for human use under current FDA guidance. A pharmacy that does so is operating outside the regulatory framework, and both the pharmacy and the prescribing provider are exposed to regulatory and legal liability.

What This Means for 503B Outsourcing Facilities

503B outsourcing facilities face the same restriction. These facilities can produce large batches of compounded drugs for healthcare facilities, but only using substances on the approved list. CJC-1295 and Ipamorelin are not on that list.

Tesamorelin Compounding

Tesamorelin occupies a different position. Because Egrifta SV® is an FDA-approved drug, there are limited circumstances under which compounding pharmacies might compound tesamorelin — primarily when a patient has a documented clinical need that the commercially available product cannot meet (e.g., a specific allergen sensitivity to an excipient). However, compounding tesamorelin into a multi-peptide blend with unapproved substances is not a recognized legal pathway.

---

Enforcement Actions

The FDA has taken enforcement action against companies marketing unapproved peptide products, including growth hormone secretagogues. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity related to this class of compounds.^[1]

What the general enforcement pattern looks like, based on publicly available FDA activity:

• The FDA has issued warning letters to compounding pharmacies and online vendors marketing CJC-1295, Ipamorelin, and related peptides for human use without an approved application.
• The FDA's Office of Criminal Investigations (OCI) has coordinated with the Department of Justice on cases involving the distribution of unapproved injectable drugs, including peptide secretagogues.
• The Federal Trade Commission (FTC) has taken action against vendors making unsubstantiated health claims about peptide products marketed directly to consumers.

The enforcement risk falls most heavily on sellers and prescribers, not individual patients possessing small quantities for personal use — but that doesn't mean patients face zero risk, particularly when importing from overseas.

---

Prescription vs. Over-the-Counter vs. Research Use

Can a Doctor Prescribe This Blend?

No. A physician can legally prescribe an FDA-approved drug for an off-label use — that's a well-established medical and legal practice. But the Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg Blend is not FDA-approved for any indication. Prescribing it isn't "off-label" — it's prescribing an unapproved drug, which is a different legal category entirely. (More on this distinction in the next section.)

A physician could, in theory, prescribe Egrifta SV® (standalone tesamorelin) off-label for a non-HIV patient, though that carries its own liability considerations and insurance won't cover it. But that's a separate product from this blend.

"Research Use Only" — Not a Loophole

Vendors selling this blend labeled "for research use only" or "not for human consumption" are not providing you a legal shield. That label is a seller's attempt to sidestep FDA drug regulations by framing the product as a laboratory chemical rather than a drug. The FDA evaluates products based on their intended use, not just their label. If a product is being sold with the understanding — even implicit — that buyers will use it on themselves, the FDA can and does treat it as an unapproved drug.^[1]

From a practical standpoint: buying a "research use only" peptide blend online, injecting it yourself, and telling a customs agent "it's for research" is not a legal defense. It's also genuinely risky from a health standpoint, because research-grade peptides are not manufactured under pharmaceutical-grade conditions. Purity, sterility, and accurate dosing are not guaranteed.

Gray Market Products

The gray market for peptide secretagogues is substantial. Products are sold through domestic websites, international suppliers, and social media channels. Buyers face several real risks:

• Purity and contamination: A 2023 analysis of commercially available "research peptides" found significant discrepancies between labeled and actual peptide content, with some products containing bacterial endotoxins at levels that would cause fever and inflammatory reactions in humans.^[5]
• Legal exposure: While individual possession of small quantities for personal use is rarely prosecuted, importation from overseas can trigger customs seizure, and larger quantities can attract more serious attention.
• No recourse if harmed: If you're injured by a product purchased through gray market channels, your legal and medical recourse is extremely limited.

---

What "Off-Label" Actually Means

This distinction matters more than most patients realize, and it's one that some clinics deliberately blur.

Off-label prescribing means a physician prescribes an FDA-approved drug for a use, patient population, or dosage not specified in the FDA-approved labeling. It's legal, common, and accounts for roughly 20% of all prescriptions written in the United States.^[6] A physician who prescribes Egrifta SV® to a non-HIV patient for body composition purposes is prescribing off-label — that's legal, if potentially inadvisable from a liability standpoint.

Prescribing the Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg Blend is not off-label prescribing. There is no approved drug to prescribe "off-label." A physician who writes a prescription for this blend is directing a pharmacy to dispense an unapproved drug — a violation of the FD&C Act. The liability exposure for that physician is meaningfully different from off-label prescribing, and the malpractice implications are more serious.

If a clinic tells you they're prescribing this blend "off-label," that's either a misunderstanding of the regulatory framework or a misrepresentation. Either way, it's worth asking follow-up questions.

---

State-Level Variations

Federal law sets the floor for peptide regulation, but state pharmacy boards and medical boards add their own layer.

State Pharmacy Board Positions

Several state pharmacy boards have issued specific guidance restricting the compounding of peptides that appear on the FDA's Category 2 list. California, Florida, and Texas — states with large compounding pharmacy sectors — have all seen board-level enforcement activity related to peptide secretagogues. The specifics evolve frequently; checking your state pharmacy board's current guidance is worth the 10 minutes.

Telemedicine and Prescribing Rules

The expansion of telemedicine has created a new vector for peptide prescribing. Some telehealth platforms have offered peptide protocols through quick online consultations, sometimes without adequate patient evaluation. Following the COVID-19 public health emergency, the DEA and HHS have been working on updated rules governing controlled substance prescribing via telemedicine, and some states have independently tightened their telemedicine prescribing standards. While peptide secretagogues aren't controlled substances, state medical boards can still discipline physicians who prescribe unapproved drugs through inadequate telemedicine encounters.

State-Level Enforcement

State attorneys general have, in some instances, pursued action against in-state compounding pharmacies and clinics operating outside federal and state pharmacy law. These cases typically involve a pattern of violations rather than isolated incidents, but they're a real enforcement mechanism.

---

International Status

European Union (EMA)

The European Medicines Agency has not approved any formulation of CJC-1295 (no DAC) or Ipamorelin for human use. Tesamorelin is not approved by the EMA. All three components would be classified as unapproved medicinal products under EU pharmaceutical law, making their manufacture, sale, and distribution for human use illegal across EU member states.

United Kingdom (MHRA)

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has not approved any of the three components for human use. The MHRA has issued guidance classifying growth hormone secretagogues as prescription-only medicines requiring marketing authorization — authorization that none of these peptides hold in the UK.

Australia (TGA)

The Therapeutic Goods Administration (TGA) classifies growth hormone secretagogues as Schedule 4 (prescription-only) substances in Australia. Ipamorelin and CJC-1295 are not included on the Australian Register of Therapeutic Goods (ARTG) for any indication, making their importation and supply for human use illegal without specific authorization.

Canada (Health Canada)

Health Canada has not approved CJC-1295, Ipamorelin, or the triple-peptide blend for any human indication. Tesamorelin is approved in Canada under the brand name Egrifta® for HIV-associated lipodystrophy, mirroring the US approval. The blend as a whole has no regulatory pathway in Canada.

---

What This Means for Patients

If you're considering peptide therapy for growth hormone optimization, here's how to protect yourself.

How to Verify a Clinic Is Operating Legally

A legitimate peptide therapy clinic will only prescribe peptides that are legally available through FDA-compliant channels. As of March 2026, that means sermorelin — a GHRH analog that has maintained compounding eligibility — is among the growth hormone secretagogues with a clearer legal pathway. Ask any clinic you're considering:

1. Which pharmacy compounds your peptides? It should be a licensed 503A or 503B facility. Ask for the pharmacy's name and verify it's licensed with your state board.
2. Is the peptide on the FDA's approved bulk drug substance list? A legitimate clinic will know the answer.
3. What's the prescribing indication? If they can't articulate a specific medical rationale, that's a red flag.
4. Is there a legitimate patient evaluation before prescribing? Labs, history, physical exam — not just an online questionnaire.

Red Flags

• A clinic offering this specific Tesamorelin/CJC-1295/Ipamorelin blend as a routine protocol, presented as a "prescription" product, without acknowledging its regulatory status.
• Peptides shipped directly to you without going through a licensed pharmacy.
• "Research use only" products sold with dosing instructions for human use.
• Pricing that seems too low for pharmaceutical-grade compounded products (research-grade peptides are cheaper because they're not manufactured to pharmaceutical standards).

How to Report Suspicious Sellers

If you encounter a vendor selling this blend for human use without appropriate regulatory compliance, you can report them to:

• FDA MedWatch: fda.gov/safety/medwatch (adverse events and unsafe products)
• FDA Office of Criminal Investigations: for suspected criminal violations
• Your state pharmacy board: for compounding pharmacies operating outside state law
• FTC: for deceptive marketing claims

---

Legal Alternatives

If you're pursuing growth hormone axis optimization for legitimate clinical reasons, there are legal pathways — they're just narrower than what some clinics advertise.

Sermorelin

Sermorelin is a GHRH analog (the first 29 amino acids of endogenous GHRH) that has maintained a more favorable regulatory position than CJC-1295. While its status in compounding has also faced scrutiny, it has a longer history of clinical use and a clearer regulatory record. Talk to a licensed provider about whether sermorelin is currently available through a compliant compounding pharmacy in your state.

Tesamorelin (Standalone, Egrifta SV®)

If you have HIV-associated lipodystrophy, tesamorelin as Egrifta SV® is the FDA-approved option. For other indications, off-label prescribing is a conversation to have with an endocrinologist who understands the liability landscape.

FDA-Approved Growth Hormone

Recombinant human growth hormone (rhGH) — including brands like Norditropin®, Genotropin®, and Humatrope® — is FDA-approved for specific indications including adult growth hormone deficiency. If you have a documented deficiency confirmed by stimulation testing, this is the most legally straightforward path. See our growth hormone therapy overview for more detail.

Ibutamoren (MK-677)

Ibutamoren (MK-677) is an oral ghrelin mimetic that activates the same GHS-R1a receptor as Ipamorelin. Its regulatory status is distinct from injectable peptides, though it also lacks FDA approval for human use. It's worth understanding the differences before assuming it's a simple substitute.

You can also use the MyPeptideMatch Clinic Finder to identify providers who work within the current regulatory framework and can advise you on legally available options.

---

What the Evidence Does Not Show

Pending FDA Decisions

The FDA's bulk drug substance review process for peptides has been ongoing, and the agency has not finalized all decisions. The regulatory status of some peptides in this class could shift — in either direction — as the FDA completes its review cycle. There's no public timeline for when final determinations on all peptide secretagogues will be issued.

Combination Formulation Data

There is essentially no published clinical trial data on this specific triple-peptide blend at the 12mg combined dose. The preclinical and in vitro research on the individual components — while mechanistically interesting — does not establish safety or efficacy for the combination in humans. The synergistic effects of simultaneously activating GHRH receptors via cAMP/PKA cascades and GHS-R1a receptors via calcium mobilization are theoretically appealing, but theoretical appeal is not clinical evidence.

Long-Term Safety

Even for the individual components with more research behind them, long-term human safety data is limited. The immunogenicity question — whether sustained use of synthetic peptide analogs leads to clinically meaningful antibody formation — hasn't been answered by well-powered prospective studies.

The Regulatory Trajectory

Whether the FDA will ever approve a growth hormone secretagogue blend for general clinical use is genuinely uncertain. The agency's recent posture toward compounded peptides has been restrictive rather than permissive, and the pathway from research-stage peptide to approved drug typically takes 10-15 years and hundreds of millions of dollars in clinical development costs.

---

FAQ

Is the Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg Blend legal in the US?

Not for human use. The blend is classified as research use only, with no FDA approval for any clinical indication. Selling it for human use, prescribing it, or compounding it through a licensed pharmacy for patient administration all fall outside current US regulatory law.

Can my doctor prescribe this blend?

No. A physician can prescribe FDA-approved drugs off-label, but this blend has no FDA approval. Prescribing it constitutes directing a pharmacy to dispense an unapproved drug — a violation of the FD&C Act. A physician who does so takes on significant regulatory and malpractice exposure.

Is it legal to buy this blend online?

Buying it from a domestic vendor selling it for human use means purchasing an unapproved drug — which is illegal under the FD&C Act regardless of what the label says. Importing it from overseas adds customs law to the equation. Small personal-use quantities are rarely prosecuted, but the product can be seized, and there's no guarantee of purity or sterility.

What happens if I'm caught with this blend?

Individual possession for personal use is not typically a criminal enforcement priority for federal agencies, which focus on manufacturers and distributors. However, customs can seize imported shipments, and depending on quantity and circumstances, state law may also apply. The more significant risk is health-related: using an unregulated injectable product of unknown purity.

Is this blend a controlled substance?

No. None of the three components — tesamorelin, CJC-1295 (no DAC), or ipamorelin — are scheduled under the Controlled Substances Act (CSA) as of March 2026. The legal restrictions come from FDA drug approval law, not DEA scheduling.

Can compounding pharmacies make this blend?

No. CJC-1295 (no DAC) and Ipamorelin are on the FDA's Category 2 bulk drug substance list, meaning the FDA has determined they should not be used in compounded preparations for human use.^[3] A pharmacy that compounds this blend is operating outside the 503A/503B regulatory framework.

Is "research use only" labeling a legal protection?

No. The FDA evaluates products based on intended use. If a "research use only" product is being sold with the understanding that buyers will use it on themselves, the FDA treats it as an unapproved drug. The label provides no legal protection to buyers or sellers.

Has anyone been prosecuted for this specific blend?

The FDA has taken enforcement action against companies marketing unapproved growth hormone secretagogue products. Consult FDA.gov for current enforcement activity. Prosecution of individual end-users for personal possession is rare, but enforcement against manufacturers, distributors, and prescribers is ongoing.

What's the safest legal option if I want growth hormone support?

Talk to a board-certified endocrinologist or an anti-aging physician who works within the current regulatory framework. Sermorelin has a more established compounding history, and FDA-approved recombinant human growth hormone is available for documented adult growth hormone deficiency. Use the MyPeptideMatch Clinic Finder to locate providers who can navigate this with you legally.

Could the legal status of this blend change?

Yes, though the trajectory is unclear. The FDA's bulk drug substance review process is ongoing, and regulatory positions can shift. For the most current status, check FDA.gov's compounding drug information page and consult a licensed provider before starting any protocol.

---

References

1. U.S. Food and Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." FDA.gov. Accessed March 2026. Available at: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdca

2. U.S. Food and Drug Administration. "Egrifta SV (tesamorelin) for injection — Prescribing Information." BLA 022505. FDA.gov. Approved 2010; reformulated product approved 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000TOC.cfm

3. U.S. Food and Drug Administration. "Bulk Drug Substances That Raise Significant Safety Risks (Category 2) — 503B Outsourcing Facilities." Federal Register / FDA Compounding Guidance. FDA.gov. Accessed March 2026. Available at: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdca

4. U.S. Food and Drug Administration. "Compounding Laws and Policies — Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act." FDA.gov. Accessed March 2026. Available at: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies

5. Chua DB, et al. "Purity and Labeling Accuracy of Commercially Available Research Peptides: An Independent Analysis." J Anal Toxicol. 2023;47(4):312-319. PMID: 36987234

6. Wittich CM, Burkle CM, Lanier WL. "Ten Common Questions (and Their Answers) About Off-Label Drug Use." Mayo Clin Proc. 2012;87(10):982-990. PMID: 22877654

---

Legal status last verified: March 2026. Regulatory classifications are subject to change. Consult FDA.gov and a licensed healthcare provider for the most current information before making any clinical decisions.

---

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, legal advice, or a recommendation to use any specific product or treatment. The regulatory status of peptides changes frequently. Consult a licensed healthcare provider before starting any treatment, and consult a licensed attorney for legal questions specific to your situation. MyPeptideMatch.com does not endorse the use of any unapproved drug or research chemical for human administration.